Literature DB >> 2137938

The TcR-CD3 complex is required for activation of human lymphocytes with staphylococcal enterotoxin A.

P A Lando1, M Dohlsten, T Kalland, H O Sjögren, R Carlsson.   

Abstract

The involvement of the T-cell receptor (TcR)-CD3 complex in activation of human mononuclear cells by staphylococcal enterotoxin A (SEA) was investigated. TcR-CD3 molecular complex expression was modulated with monoclonal anti-CD3 antibodies. The proliferative response of such modulated cells to optimal doses of phytohaemagglutinin and monoclonal anti-CD3 antibodies and to suboptimal doses of SEA was greatly impaired. In concentrations above 1 ng/ml, SEA could also activate the modulated cells to a certain extent, apparently due to reexpression of low levels of the TcR-CD3 molecular complex during incubation. TcR-CD3 modulation decreased the ability of SEA-activated cells to produce interleukin 2 and gamma interferon. Analysis of cloned cells revealed that SEA could only activate CD3+ but not CD3- clones. Both CD4+ and CD8+ clones were activated. The results show that SEA activates human T cells by a mechanism involving the TcR-CD3 molecular complex.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2137938     DOI: 10.1111/j.1365-3083.1990.tb02752.x

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  5 in total

1.  Bacterial superantigens as anti-tumour agents: induction of tumour cytotoxicity in human lymphocytes by staphylococcal enterotoxin A.

Authors:  P A Lando; G Hedlund; M Dohlsten; T Kalland
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

2.  Staphylococcal enterotoxin A-induced fever is associated with increased circulating levels of cytokines in rabbits.

Authors:  W T Huang; M T Lin; S J Won
Journal:  Infect Immun       Date:  1997-07       Impact factor: 3.441

3.  T cell killing of human colon carcinomas by monoclonal-antibody-targeted superantigens.

Authors:  P A Lando; M Dohlsten; G Hedlund; E Akerblom; T Kalland
Journal:  Cancer Immunol Immunother       Date:  1993       Impact factor: 6.968

Review 4.  Monoclonal antibodies and superantigens: a novel therapeutic approach.

Authors:  T Kalland; M Dohlsten; P Lind; A Sundstedt; L Abrahmsén; G Hedlund; P Björk; P A Lando; M Björklund
Journal:  Med Oncol Tumor Pharmacother       Date:  1993

Review 5.  Targeting of superantigens.

Authors:  T Kalland; M Dohlsten; L Abrahmsén; G Hedlund; P Björk; P A Lando; A Sundstedt; E Akerblom; P Lind
Journal:  Cell Biophys       Date:  1993 Jan-Jun
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.